CA2699040A1 - Perharidines - Google Patents

Perharidines Download PDF

Info

Publication number
CA2699040A1
CA2699040A1 CA2699040A CA2699040A CA2699040A1 CA 2699040 A1 CA2699040 A1 CA 2699040A1 CA 2699040 A CA2699040 A CA 2699040A CA 2699040 A CA2699040 A CA 2699040A CA 2699040 A1 CA2699040 A1 CA 2699040A1
Authority
CA
Canada
Prior art keywords
groups
group
formula
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2699040A
Other languages
English (en)
French (fr)
Inventor
Laurent Meijer
Karima Bettayeb
Herve Galons
Luc Demange
Nassima Oumata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Rennes
Université Paris Descartes
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2699040A1 publication Critical patent/CA2699040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2699040A 2007-09-12 2008-09-12 Perharidines Abandoned CA2699040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2007/003655 WO2009034411A1 (en) 2007-09-12 2007-09-12 Perharidines as cdk inhibitors
IBPCT/IB2007/003655 2007-09-12
PCT/IB2008/003106 WO2009034475A2 (en) 2007-09-12 2008-09-12 Perharidines as cdk inhibitors

Publications (1)

Publication Number Publication Date
CA2699040A1 true CA2699040A1 (en) 2009-03-19

Family

ID=39773126

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699040A Abandoned CA2699040A1 (en) 2007-09-12 2008-09-12 Perharidines

Country Status (10)

Country Link
US (1) US8450342B2 (enExample)
EP (1) EP2185557A2 (enExample)
JP (1) JP2010539155A (enExample)
KR (1) KR20100075907A (enExample)
CN (1) CN101809020A (enExample)
BR (1) BRPI0816799A2 (enExample)
CA (1) CA2699040A1 (enExample)
MX (1) MX2010002477A (enExample)
RU (1) RU2498984C2 (enExample)
WO (2) WO2009034411A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN105481858B (zh) * 2014-10-11 2019-05-17 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CN111217814B (zh) * 2018-11-26 2022-08-26 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
US20230115907A1 (en) 2019-12-20 2023-04-13 Evopoint Biosciences Co., Ltd. Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN115104576A (zh) * 2022-07-12 2022-09-27 河北医科大学 Cdk5调控eEF2在糖尿病肾病防治中的操作方法
CN118598874A (zh) * 2024-05-21 2024-09-06 江南大学 一种取代的9h嘌呤类化合物、药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU566842A1 (ru) * 1976-01-06 1977-07-30 Донецкое Отделение Физико-Органической Химии Института Физической Химии Им.Л.В.Писаржевского Ан Украинской Сср Способ получени замещенных имидазопиридинов
AU7738000A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
CA2491680C (en) * 2002-07-02 2012-04-17 Southern Research Institute Inhibitors of ftsz and uses thereof
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
TW200616624A (en) * 2004-09-09 2006-06-01 Solvay Pharm Bv 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
EP1824850A2 (en) * 2004-12-09 2007-08-29 Nycomed GmbH SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION

Also Published As

Publication number Publication date
KR20100075907A (ko) 2010-07-05
CN101809020A (zh) 2010-08-18
RU2498984C2 (ru) 2013-11-20
WO2009034411A1 (en) 2009-03-19
EP2185557A2 (en) 2010-05-19
US20100280065A1 (en) 2010-11-04
RU2010108507A (ru) 2011-10-20
WO2009034475A3 (en) 2009-08-13
WO2009034475A2 (en) 2009-03-19
BRPI0816799A2 (pt) 2015-03-03
MX2010002477A (es) 2010-08-09
US8450342B2 (en) 2013-05-28
JP2010539155A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
TW582998B (en) New pyridine-substituted pyrazolopyridine derivatives
Wissner et al. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
JP6104377B2 (ja) 線維芽細胞成長因子受容体の阻害剤
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
JP5583968B2 (ja) オキソ置換イミダゾ［１，２ｂ］ピリダジン、その調製方法、及び医薬としての使用
US20100280065A1 (en) Perharidines as cdk inhibitors
Cao et al. Synthesis and in vitro cytotoxic evaluation of 1, 3-bisubstituted and 1, 3, 9-trisubstituted β-carboline derivatives
MXPA02001108A (es) Pieridinonas como inhibidores de la cinasa.
CA2494127A1 (en) Pyrimido compounds having antiproliferative activity
Zhang et al. Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants
Ghanem et al. Design and synthesis of novel imidazo [4, 5-b] pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity
CN107686477B (zh) 作为cdk4/6抑制剂的新型化合物及其应用
JP2020520960A (ja) アザアリール誘導体、その製造方法および薬学上の応用
JP2019501904A (ja) Ｄｎａメチルトランスフェラーゼの阻害剤としての２，４，６，７−四置換キノリン化合物
CN108290899B (zh) 一种取代的吡咯并嘧啶化合物及其应用
HK1255804A1 (zh) 作为双重dyrk1/clk1抑制剂的新的咪唑并[4，5-b]吡啶衍生物
Zhang et al. Mechanism-based design, synthesis and biological studies of N5-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents
Lougiakis et al. Synthesis, cytotoxic activity evaluation and mechanistic investigation of novel 3, 7-diarylsubstituted 6-azaindoles
CA2779184A1 (en) Protein kinase inhibitors
CN115246822B (zh) 嘧啶类化合物及其制备方法和用途
Cheremnykh et al. Aminocarbonylation of 2-(N-substituted) 5-iodobenzoates: synthesis of glyoxylamido-anthranilates, their cytotoxicity and molecular modeling study
CN108299312A (zh) 一组嘧啶类衍生物及其在制备抗肿瘤药物中的应用
Biagi et al. New N6-or N (9)-hydroxyalkyl substituted 8-azaadenines or adenines as effective A1 adenosine receptor ligands
Arava et al. New reagents from “N, N-Dimethylaminomethoxy methylenium methyl sulphate”-Synthesis of 3-Amino-4-cyano pyrazole
CN120943837A (zh) 作为酪氨酸激酶抑制剂的杂环化合物

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20140912